Project Grant R01CA295861
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to support research by Oncotab, Inc. on optimized targeted radiotherapy for pancreatic cancer. The key objectives are to develop a tumor-specific antibody (HTAB004) and a tandem single-chain variable fragment (scFv) targeting agent labeled with alpha and beta particle-emitting radioisotopes. This research aims to overcome the challenge of the desmoplastic stroma in pancreatic...
- This $677,176 federal Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development of an interstitial chemophototherapy (I-CPT) approach for treating locally advanced pancreatic cancer. The grantee, The Research Foundation For The State University Of New York (RF SUNY), will advance its long-circulating liposomal irinotecan formulation integrated with porphyrin-phospholipid (IRT-POP) for photoablation of large...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to the University of Miami to support research into a novel immunotherapy approach for pancreatic cancer using microRNA-29a. The goal is to determine how microRNA-29a can regulate T cell exhaustion and restore anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC), which has a very low 5-year survival rate of 12%. The research will utilize the KPC mouse model of PDAC...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $109,080 to The Trustees of Columbia University in the City of New York to conduct a Phase II, randomized controlled trial evaluating a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma. The trial will compare a combination regimen of Motixafortide, Cemiplimab, Gemcitabine, and Nab-Paclitaxel against the standard Gemcitabine and Nab-Paclitaxel...
- The National Cancer Institute awarded a $119,858 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The award supports research to elucidate mechanisms governing immune surveillance and resistance to antitumor T cell response in pancreatic cancer. The project aims to identify ways to safely promote T cell-mediated destruction of pancreatic cancer through combinatorial immunotherapies....
- The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...
- This $410,115 Project Grant was awarded by the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), to the University of California, San Diego (UC San Diego) to support research aimed at improving preclinical models of metastatic pancreatic cancer. The research project seeks to understand how the collagen-rich tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) drives metastasis and treatment resistance, and to develop a synthetic 3D high density...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This $151,263 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program to fund a research project titled "Understanding Paracrine Interactions Induced by Morphogens in PDAC" at The Trustees of Columbia University in the City of New York. The project aims to identify how active morphogen signaling shapes local immunosuppression in the pancreatic tumor microenvironment by studying the interactions between malignant...